tiprankstipranks
Trending News
More News >
Procter & Gamble Health Ltd. (IN:PGHL)
:PGHL
India Market
Advertisement

Procter & Gamble Health Ltd. (PGHL) AI Stock Analysis

Compare
3 Followers

Top Page

IN:PGHL

Procter & Gamble Health Ltd.

(PGHL)

Select Model
Select Model
Select Model
Outperform 75 (OpenAI - 4o)
Rating:75Outperform
Price Target:
₹7,047.00
▲(13.37% Upside)
Procter & Gamble Health Ltd. exhibits strong financial performance with robust profitability and a stable balance sheet, which are the most significant factors contributing to the score. Technical analysis indicates a stable price trend with neutral market sentiment. The valuation is moderate, with a high P/E ratio balanced by a reasonable dividend yield. The absence of earnings call data and corporate events does not impact the score.

Procter & Gamble Health Ltd. (PGHL) vs. iShares MSCI India ETF (INDA)

Procter & Gamble Health Ltd. Business Overview & Revenue Model

Company DescriptionProcter & Gamble Health Ltd. (PGHL) is a subsidiary of Procter & Gamble Company, specializing in health and wellness products. The company operates within the healthcare sector, focusing on a variety of consumer health products, including over-the-counter medications, dietary supplements, and oral health products. PGHL aims to improve consumer health and well-being through its scientifically backed and trusted product offerings.
How the Company Makes MoneyPGHL generates revenue primarily through the sale of its health-related products, which are marketed under well-known brands. The company utilizes a multi-channel distribution strategy, including retail partnerships, e-commerce platforms, and direct-to-consumer sales. Key revenue streams include prescription and over-the-counter medications, vitamins and supplements, and oral hygiene products. Additionally, PGHL benefits from strategic partnerships with healthcare providers and organizations that enhance product visibility and consumer trust. The company's strong brand equity and continued investment in research and development also contribute significantly to its earnings by ensuring a steady pipeline of innovative health solutions.

Procter & Gamble Health Ltd. Financial Statement Overview

Summary
Procter & Gamble Health Ltd. exhibits a strong financial position across all verticals. The income statement reflects robust profitability and growth, while the balance sheet indicates excellent financial stability with low leverage. The cash flow statement is positive, with strong cash generation capabilities. The company is well-positioned for future growth, though there is room for improvement in cost management and operational efficiency.
Income Statement
85
Very Positive
Procter & Gamble Health Ltd. demonstrates strong profitability with a consistent increase in net profit margin and EBIT margin over the years. The company has shown a healthy revenue growth rate of 7.42% in the most recent year, indicating robust sales performance. However, the gross profit margin has declined slightly, suggesting increased cost pressures. Overall, the income statement reflects a solid financial performance with room for improvement in cost management.
Balance Sheet
90
Very Positive
The balance sheet of Procter & Gamble Health Ltd. is very strong, characterized by a low debt-to-equity ratio of 0.014, indicating minimal leverage and financial risk. The return on equity is impressive at 58.21%, showcasing efficient use of shareholder funds to generate profits. The equity ratio is healthy, reflecting a strong capital structure. Overall, the balance sheet is robust, with excellent financial stability and low risk.
Cash Flow
80
Positive
The cash flow statement shows a positive trajectory with strong free cash flow to net income ratio of 0.95, indicating efficient cash generation relative to net income. The operating cash flow to net income ratio is slightly lower at 0.82, suggesting room for improvement in operational efficiency. The free cash flow growth rate is exceptionally high, but this is due to a low base effect. Overall, the cash flow position is solid, with potential for enhanced operational cash flow management.
BreakdownTTMDec 2025Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue12.18B12.46B11.51B12.30B10.92B9.91B
Gross Profit7.69B6.84B8.21B8.68B7.25B6.52B
EBITDA3.59B4.38B3.07B3.43B2.81B2.64B
Net Income2.51B3.13B2.01B2.29B1.93B1.77B
Balance Sheet
Total Assets7.94B7.94B7.94B11.01B8.94B9.86B
Cash, Cash Equivalents and Short-Term Investments2.06B1.89B2.44B4.53B3.19B4.64B
Total Debt76.20M76.20M95.60M120.00M28.30M76.10M
Total Liabilities2.57B2.57B2.56B3.50B2.77B2.82B
Stockholders Equity5.37B5.37B5.38B7.51B6.16B7.04B
Cash Flow
Free Cash Flow459.90M1.67B2.07B1.94B1.32B1.95B
Operating Cash Flow492.20M1.76B2.28B2.36B1.70B2.47B
Investing Cash Flow-500.00K24.40M-68.70M-215.00M-255.40M-322.70M
Financing Cash Flow-1.34B-2.35B-4.18B-984.70M-2.89B-3.87B

Procter & Gamble Health Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6215.80
Price Trends
50DMA
6288.21
Negative
100DMA
6047.83
Positive
200DMA
5612.18
Positive
Market Momentum
MACD
-25.84
Positive
RSI
48.82
Neutral
STOCH
60.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PGHL, the sentiment is Positive. The current price of 6215.8 is below the 20-day moving average (MA) of 6241.30, below the 50-day MA of 6288.21, and above the 200-day MA of 5612.18, indicating a neutral trend. The MACD of -25.84 indicates Positive momentum. The RSI at 48.82 is Neutral, neither overbought nor oversold. The STOCH value of 60.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PGHL.

Procter & Gamble Health Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
₹103.18B34.332.97%2.37%23.22%
73
Outperform
₹146.53B44.800.26%10.63%7.53%
68
Neutral
₹116.22B31.801.10%1.59%-2.52%
68
Neutral
₹60.32B20.951.54%-8.69%-20.94%
67
Neutral
₹61.64B36.911.45%-6.43%-20.90%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
57
Neutral
₹26.71B32.060.41%5.32%16.91%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:PGHL
Procter & Gamble Health Ltd.
6,215.80
1,229.28
24.65%
IN:EVEREADY
Eveready Industries India Ltd
367.45
-38.93
-9.58%
IN:JYOTHYLAB
Jyothy Labs Limited
316.50
-193.92
-37.99%
IN:SURYAROSNI
Surya Roshni Limited
277.15
-44.34
-13.79%
IN:SYMPHONY
Symphony Limited
897.55
-784.86
-46.65%
IN:ZYDUSWELL
Zydus Wellness Limited
460.55
79.35
20.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 17, 2025